The Use of Ebola Convalescent Plasma to Treat Ebola Virus Disease in Resource Constrained Settings: A Perspective from the Field

Hdl Handle:
http://hdl.handle.net/10144/575434
Title:
The Use of Ebola Convalescent Plasma to Treat Ebola Virus Disease in Resource Constrained Settings: A Perspective from the Field
Authors:
van Griensven, Johan; De Weiggheleire, Anja; Delamou, Alexandre; Smith, Peter G; Edwards, Tansy; Vandekerckhove, Philippe; Ibrahima Bah, Elhadj; Colebunders, Robert; Herve, Isola; Lazaygues, Catherine; Haba, Nyankoye; Lynen, Lutgarde
Journal:
Clinical Infectious Diseases : an official publication of the Infectious Diseases Society of America
Abstract:
The clinical evaluation of convalescent plasma (CP) for the treatment of Ebola Virus Disease (EVD) in the current outbreak, predominantly affecting Guinea, Sierra Leone and Liberia, was prioritized by the World Health Organization in September 2014. In each of these countries, non-randomized comparative clinical trials were initiated. The Ebola-Tx trial in Conakry, Guinea enrolled 102 patients by July 7, 2015; no severe adverse reactions were noted. The Ebola-CP trial in Sierra Leone and the EVD001 trial in Liberia have included few patients. While no efficacy data are available yet, current field experience supports the safety, acceptability and feasibility of CP as EVD treatment. Longer-term follow-up as well as data from non-trial settings and evidence on the scalability of the intervention are required. CP sourced from within the outbreak is the most readily available source of anti-EVD antibodies. Until the advent of effective antivirals or monoclonal antibodies, CP merits further evaluation.
Publisher:
Oxford University Press
Issue Date:
10-Aug-2015
URI:
http://hdl.handle.net/10144/575434
DOI:
10.1093/cid/civ680
PubMed ID:
26261205
Language:
en
ISSN:
1537-6591
Appears in Collections:
Other Diseases

Full metadata record

DC FieldValue Language
dc.contributor.authorvan Griensven, Johanen_GB
dc.contributor.authorDe Weiggheleire, Anjaen_GB
dc.contributor.authorDelamou, Alexandreen_GB
dc.contributor.authorSmith, Peter Gen_GB
dc.contributor.authorEdwards, Tansyen_GB
dc.contributor.authorVandekerckhove, Philippeen_GB
dc.contributor.authorIbrahima Bah, Elhadjen_GB
dc.contributor.authorColebunders, Roberten_GB
dc.contributor.authorHerve, Isolaen_GB
dc.contributor.authorLazaygues, Catherineen_GB
dc.contributor.authorHaba, Nyankoyeen_GB
dc.contributor.authorLynen, Lutgardeen_GB
dc.date.accessioned2015-08-20T19:14:42Z-
dc.date.available2015-08-20T19:14:42Z-
dc.date.issued2015-08-10-
dc.identifier.citationThe use of Ebola Convalescent Plasma to treat Ebola Virus Disease in resource constrained settings: A perspective from the field. 2015: Clin. Infect. Dis.en_GB
dc.identifier.issn1537-6591-
dc.identifier.pmid26261205-
dc.identifier.doi10.1093/cid/civ680-
dc.identifier.urihttp://hdl.handle.net/10144/575434-
dc.description.abstractThe clinical evaluation of convalescent plasma (CP) for the treatment of Ebola Virus Disease (EVD) in the current outbreak, predominantly affecting Guinea, Sierra Leone and Liberia, was prioritized by the World Health Organization in September 2014. In each of these countries, non-randomized comparative clinical trials were initiated. The Ebola-Tx trial in Conakry, Guinea enrolled 102 patients by July 7, 2015; no severe adverse reactions were noted. The Ebola-CP trial in Sierra Leone and the EVD001 trial in Liberia have included few patients. While no efficacy data are available yet, current field experience supports the safety, acceptability and feasibility of CP as EVD treatment. Longer-term follow-up as well as data from non-trial settings and evidence on the scalability of the intervention are required. CP sourced from within the outbreak is the most readily available source of anti-EVD antibodies. Until the advent of effective antivirals or monoclonal antibodies, CP merits further evaluation.en_GB
dc.languageENG-
dc.language.isoenen
dc.publisherOxford University Pressen_GB
dc.rightsArchived with thanks to Clinical Infectious Diseases' open access: an official publication of the Infectious Diseases Society of Americaen_GB
dc.titleThe Use of Ebola Convalescent Plasma to Treat Ebola Virus Disease in Resource Constrained Settings: A Perspective from the Fielden
dc.identifier.journalClinical Infectious Diseases : an official publication of the Infectious Diseases Society of Americaen_GB

Related articles on PubMed

All Items in MSF are protected by copyright, with all rights reserved, unless otherwise indicated.